Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Antibe Therapeutics (ATBPF)
OTHER OTC:ATBPF
RESEARCH TOOLSreports
Antibe Therapeutics (ATBPF) Stock Price & Analysis
108 Followers
ATBPF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.11 - $0.89
Previous Close$0.22
Volume17.93K
Average Volume (3M)N/A
Market Cap
$7.50M
Enterprise Value-$10.70M
Total Cash (Recent Filing)C$24.91M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding52,637,091
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.20
R-Squared0.00566
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-37.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Antibe Therapeutics News
PremiumCompany Announcements
Antibe Therapeutics Faces Receivership and Delisting
PremiumCompany Announcements
Antibe Therapeutics Seeks Crucial Stay Extension
PremiumCompany Announcements
Antibe Therapeutics Gains Creditor Protection
PremiumCompany Announcements
Antibe Therapeutics Seeks Creditor Protection
PremiumCompany Announcements
Antibe Therapeutics Faces FDA Hold and Legal Challenges
PremiumCompany Announcements
Antibe Therapeutics Showcases Non-Opioid Pain DrugOptions Prices
Currently, No data available
---
Ownership Overview
28.56% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
71.44% Public Companies and
Individual Investors
ATBPF FAQ
What was Antibe Therapeutics’s price range in the past 12 months?
Antibe Therapeutics lowest stock price was $0.11 and its highest was $0.89 in the past 12 months.
What is Antibe Therapeutics’s market cap?
Currently, no data Available
When is Antibe Therapeutics’s upcoming earnings report date?
Antibe Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 24 days.
How were Antibe Therapeutics’s earnings last quarter?
Currently, no data Available
Is Antibe Therapeutics overvalued?
According to Wall Street analysts Antibe Therapeutics’s price is currently Overvalued.
Does Antibe Therapeutics pay dividends?
Antibe Therapeutics does not currently pay dividends.
What is Antibe Therapeutics’s EPS estimate?
Antibe Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Antibe Therapeutics have?
Antibe Therapeutics has 52,651,260 shares outstanding.
What happened to Antibe Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Antibe Therapeutics?
Currently, no hedge funds are holding shares in ATBPF
---
Antibe Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Antibe Therapeutics
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics, and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places. The company was founded by Andre Buret, John Wallace and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.
---
ATBPF Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering ATBPF
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-38.15%
reiterated a buy rating 5 months ago
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -38.15% per trade.
---